Literature DB >> 29466596

Acute Respiratory Distress Syndrome: Advances in Diagnosis and Treatment.

Eddy Fan1,2,3,4, Daniel Brodie5, Arthur S Slutsky1,4,6.   

Abstract

Importance: Acute respiratory distress syndrome (ARDS) is a life-threatening form of respiratory failure that affects approximately 200 000 patients each year in the United States, resulting in nearly 75 000 deaths annually. Globally, ARDS accounts for 10% of intensive care unit admissions, representing more than 3 million patients with ARDS annually. Objective: To review advances in diagnosis and treatment of ARDS over the last 5 years. Evidence Review: We searched MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews from 2012 to 2017 focusing on randomized clinical trials, meta-analyses, systematic reviews, and clinical practice guidelines. Articles were identified for full text review with manual review of bibliographies generating additional references. Findings: After screening 1662 citations, 31 articles detailing major advances in the diagnosis or treatment of ARDS were selected. The Berlin definition proposed 3 categories of ARDS based on the severity of hypoxemia: mild (200 mm Hg<Pao2/Fio2≤300 mm Hg), moderate (100 mm Hg<Pao2/Fio2≤200 mm Hg), and severe (Pao2/Fio2 ≤100 mm Hg), along with explicit criteria related to timing of the syndrome's onset, origin of edema, and the chest radiograph findings. The Berlin definition has significantly greater predictive validity for mortality than the prior American-European Consensus Conference definition. Clinician interpretation of the origin of edema and chest radiograph criteria may be less reliable in making a diagnosis of ARDS. The cornerstone of management remains mechanical ventilation, with a goal to minimize ventilator-induced lung injury (VILI). Aspirin was not effective in preventing ARDS in patients at high-risk for the syndrome. Adjunctive interventions to further minimize VILI, such as prone positioning in patients with a Pao2/Fio2 ratio less than 150 mm Hg, were associated with a significant mortality benefit whereas others (eg, extracorporeal carbon dioxide removal) remain experimental. Pharmacologic therapies such as β2 agonists, statins, and keratinocyte growth factor, which targeted pathophysiologic alterations in ARDS, were not beneficial and demonstrated possible harm. Recent guidelines on mechanical ventilation in ARDS provide evidence-based recommendations related to 6 interventions, including low tidal volume and inspiratory pressure ventilation, prone positioning, high-frequency oscillatory ventilation, higher vs lower positive end-expiratory pressure, lung recruitment maneuvers, and extracorporeal membrane oxygenation. Conclusions and Relevance: The Berlin definition of acute respiratory distress syndrome addressed limitations of the American-European Consensus Conference definition, but poor reliability of some criteria may contribute to underrecognition by clinicians. No pharmacologic treatments aimed at the underlying pathology have been shown to be effective, and management remains supportive with lung-protective mechanical ventilation. Guidelines on mechanical ventilation in patients with acute respiratory distress syndrome can assist clinicians in delivering evidence-based interventions that may lead to improved outcomes.

Entities:  

Mesh:

Year:  2018        PMID: 29466596     DOI: 10.1001/jama.2017.21907

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  338 in total

1.  Acute respiratory distress syndrome (ARDS) phenotyping.

Authors:  M Shankar-Hari; E Fan; N D Ferguson
Journal:  Intensive Care Med       Date:  2018-12-05       Impact factor: 17.440

2.  Single cell RNA sequencing identifies an early monocyte gene signature in acute respiratory distress syndrome.

Authors:  Yale Jiang; Brian R Rosborough; Jie Chen; Sudipta Das; Georgios D Kitsios; Bryan J McVerry; Rama K Mallampalli; Janet S Lee; Anuradha Ray; Wei Chen; Prabir Ray
Journal:  JCI Insight       Date:  2020-07-09

3.  Poldip2 deficiency protects against lung edema and vascular inflammation in a model of acute respiratory distress syndrome.

Authors:  Steven J Forrester; Qian Xu; Daniel S Kikuchi; Derick Okwan-Duodu; Ana Carolina Campos; Elizabeth A Faidley; Guogang Zhang; Bernard Lassègue; Ruxana T Sadikot; Kathy K Griendling; Marina S Hernandes
Journal:  Clin Sci (Lond)       Date:  2019-01-25       Impact factor: 6.124

4.  Prognosis value of Serum Cytokine levels among burn-induced ards patients.

Authors:  L N Nguyen; D H Tran; K H Dong
Journal:  Ann Burns Fire Disasters       Date:  2018-09-30

5.  [52-year-old female with community-acquired pneumonia, acute respiratory distress syndrome : Preparation for the medical specialist examination: Part 25].

Authors:  A Güldner; P Spieth
Journal:  Anaesthesist       Date:  2019-04       Impact factor: 1.041

6.  Sleep quality in survivors of critical illness: practical shortcomings unresolved.

Authors:  Mohamad F El-Khatib; Antonio M Esquinas
Journal:  Sleep Breath       Date:  2018-09-15       Impact factor: 2.816

7.  Alveolar Epithelial Cells Burn Fat to Survive Acute Lung Injury.

Authors:  Robert B Hamanaka; Gökhan M Mutlu
Journal:  Am J Respir Cell Mol Biol       Date:  2019-02       Impact factor: 6.914

8.  Change is in the air: dying to breathe oxygen in acute respiratory distress syndrome?

Authors:  Pierce Geoghegan; Sean Keane; Ignacio Martin-Loeches
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

9.  [Intensive care studies from 2017/2018].

Authors:  C J Reuß; M Bernhard; C Beynon; A Hecker; C Jungk; C Nusshag; M A Weigand; D Michalski; T Brenner
Journal:  Anaesthesist       Date:  2018-09       Impact factor: 1.041

10.  An analysis of the 28-day mortality risk factors in acute respiratory distress syndrome patients and the establishment of prediction models.

Authors:  Hui Chen; Qiong Liu; Lifeng Wang
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.